Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

CLARITHROMYCIN CRS (170 MG)

CLARITHROMYCIN CRS (170 MG)

81103-11-9

DISCOVER
CLARITHROMYCIN FOR PEAK IDENTIFICATION CRS (10 MG)

CLARITHROMYCIN FOR PEAK IDENTIFICATION CRS (10 MG)

81103-11-9

DISCOVER
Loperamide hydrochloride for system suitability

Loperamide hydrochloride for system suitability

34552-83-5

DISCOVER
METHACRYLIC ACID-ETHYL ACRYLATE COPOLYMER (1:1) - TYPE B CRS

METHACRYLIC ACID-ETHYL ACRYLATE COPOLYMER (1:1) - TYPE B CRS

NA

DISCOVER
ESKETAMINE HYDROCHLORIDE - REFERENCE SPECTRUM (N/A)

ESKETAMINE HYDROCHLORIDE - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
TILIDINE HYDROCHLORIDE HEMIHYDRATE - REFERENCE SPECTRUM (N/A

TILIDINE HYDROCHLORIDE HEMIHYDRATE - REFERENCE SPECTRUM (N/A

NA

DISCOVER
AZELASTINE HYDROCHLORIDE CRS (25 MG)

AZELASTINE HYDROCHLORIDE CRS (25 MG)

79307-93-0

DISCOVER
AZELASTINE IMPURITY B CRS (5 MG)

AZELASTINE IMPURITY B CRS (5 MG)

NA

DISCOVER
AZELASTINE IMPURITY D CRS (5 MG)

AZELASTINE IMPURITY D CRS (5 MG)

NA

DISCOVER
AZELASTINE IMPURITY E CRS (5 MG)

AZELASTINE IMPURITY E CRS (5 MG)

NA

DISCOVER
NAFTIDROFURYL IMPURITY F CRS (10 MG)

NAFTIDROFURYL IMPURITY F CRS (10 MG)

NA

DISCOVER
SPIRAPRIL FOR SYSTEM SUITABILITY CRS (15 MG)

SPIRAPRIL FOR SYSTEM SUITABILITY CRS (15 MG)

94841-17-5

DISCOVER